Acta Med. 2020, 63: 183-187

https://doi.org/10.14712/18059694.2020.61

Comparing the Efficacy of Sequential and Standard Quadruple Therapy for Eradication of H. Pylori Infection

Mohsen Razavizadeh, Abbas Arj, Maryam Madani, Hamidreza Gilassi

Department of Internal Medicine, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran

Received January 17, 2020
Accepted September 13, 2020

References

1. Pounder RE, The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995; 2: 33–9.
2. Yang J-Ch, Lu Ch-W, Lin Ch-J. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol 2014; 20(18): 5283–93. <https://doi.org/10.3748/wjg.v20.i18.5283> <PubMed>
3. Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer in Asia. J Gastroenterol Hepatol 2010; 25: 479–86. <https://doi.org/10.1111/j.1440-1746.2009.06188.x>
4. Malekzadeh R, Sotoudeh M, Derakhshan MH, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. J ClinPathol 2004; 57: 37–42.
5. Miftahussurur M. Population-Based Strategies for Helicobacter pylori-Associated Disease Management: Asian Perspective. Helicobacter pylori Res 2016; 519–42. <https://doi.org/10.1007/978-4-431-55936-8_23>
6. Fakheri H, Saberi Firoozi M, Bari Z. Eradication of Helicobacter pylori in Iran: A Review. Middle East J Dig Dis 2018; 10(1): 5–17. <https://doi.org/10.15171/mejdd.2017.84> <PubMed>
7. Moosazadeh M, Lankarani KB, Afshari M. Meta-analysis of the Prevalence of Helicobacter Pylori Infection among Children and Adults of Iran. Int J Prev Med 2016; 7: 48. <https://doi.org/10.4103/2008-7802.181756> <PubMed>
8. Muhammad Mift M, Yoshio Yamaoka. Population-Based Strategies for Helicobacter pylori-Associated Disease Management: Asian Perspective. Helicobacter pylori Res 2015; 519–42.
9. Hosseini E, Poursina F, Van de Wiele T, GhasemianSafae Hi, Adibi P. Helicobacter pylori in Iran: A systematic review on the association of genotypes and gastroduodenal diseases. J Res Med Sci 2012; 17(3): 280–92.
10. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology 2018; 155(5): 1372–82.e17. <https://doi.org/10.1053/j.gastro.2018.07.007> <PubMed>
11. Qasim A, Sebastian S, Thornton O, et al. Rifabutin- and furazolidone- based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91–6. <https://doi.org/10.1111/j.1365-2036.2004.02210.x>
12. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005; 22: 45–9. <https://doi.org/10.1111/j.1365-2036.2005.02522.x>
13. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005; 10: 157–71. <https://doi.org/10.1111/j.1523-5378.2005.00307.x>
14. Fischbach LA, Van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071–82. <https://doi.org/10.1111/j.1365-2036.2004.02248.x>
15. Graham DY, Hammoud F, El-Zimaity HM, et al. Meta-analysis: proton pump inhibitor or H2 receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17: 1229–36. <https://doi.org/10.1046/j.1365-2036.2003.01583.x>
16. Lee J, Breslin N. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 1999; 13(4): 489–96. <https://doi.org/10.1046/j.1365-2036.1999.00504.x>
17. Bigard MA, Delchier JC, Riachi G, Thibault P, Barthelemy P. One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin. Aliment Pharmacol Ther 1998; 12(4): 383–8. <https://doi.org/10.1046/j.1365-2036.1998.00315.x>
18. Deltenre M, Jonas C, van Gossum M, Buset M, Otero J, de Koster E. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients. European J Gastroenterol Hepatol 1995; 7(1): S39–S44.
19. Kashimura H, Suzuki K, Hassan M, et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13(4): 483–7. <https://doi.org/10.1046/j.1365-2036.1999.00510.x>
20. Wong FY, Chang S. Abid, et al. Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. Aliment Pharmacol Ther 2000; 14(11): 1529–35. <https://doi.org/10.1046/j.1365-2036.2000.00863.x>
21. Perri F, Villani M. Predictors of failure of Helicobacter pylori eradication with the standard. Maastricht triple therapy. Aliment Pharmacol Ther 2001; 15(7): 1023–9. <https://doi.org/10.1046/j.1365-2036.2001.01006.x>
22. Ecclissato C, Marchioretto M, Mendonca S, et al. Increased primary resistance to recommended antibiotics negatively affects Helicobacter pylori eradication. Helicobacter 2002; 7: 53–9. <https://doi.org/10.1046/j.1523-5378.2002.00056.x>
23. Rinaldi V, Zullo A. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13(2): 163–8. <https://doi.org/10.1046/j.1365-2036.1999.00462.x>
24. Zhou YQ, Xu L, Wang BF, et al. Modified sequential therapy regimen versus conventional tripletherapy for Helicobacter pylori eradication in duodenal ulcerpatients in China: a multicenter clinical comparative study. Gastroenterol Res Pract 2012; 405-425.
25. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146(8): 556–63. <https://doi.org/10.7326/0003-4819-146-8-200704170-00006>
26. Sanchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Titó L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008; 103(9): 2220–3. <https://doi.org/10.1111/j.1572-0241.2008.01924.x>
27. Yakut M, Cinar K, Seven G, Bahar K, Ozden A. Sequentialtherapy for Helicobacter pylori eradication. Turk J Gastroenterol 2010; 21(3): 206–11. <https://doi.org/10.4318/tjg.2010.0089>
28. Megraud, F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53(9): 1374–84. <https://doi.org/10.1136/gut.2003.022111> <PubMed>
29. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998; 93(12): 2330–8. <https://doi.org/10.1111/j.1572-0241.1998.00684.x>
30. Suerbaum S, Michetti P. Helicobacter pylori infection. The New England J Med 2002 347: 1175–86. <https://doi.org/10.1056/NEJMra020542>
31. Sipponen, P. Chronic Gastritis in former times and now. Helicobacter 2007; 2: 16–21. <https://doi.org/10.1111/j.1523-5378.2007.00561.x>
32. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy forHelicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146(8): 556–63. <https://doi.org/10.7326/0003-4819-146-8-200704170-00006>
33. Schnchez-Delgado J, Calvet X, Bujanda L, Gisbert JP, Tit L, Castro M. Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice. Am J Gastroenterol 2008; 103(9): 2220–3. <https://doi.org/10.1111/j.1572-0241.2008.01924.x>
34. Marshall B. Sequential therapy for Helicobacter pylori: a worthwhile effort for your patients. Ann Intern Med 2008; 148: 962–3. <https://doi.org/10.7326/0003-4819-148-12-200806170-00227>
35. Gatta L, Di Mario F, Zullo A, Vaira D. Errors in a meta-analysis of treatments for Helicobacter pylori infection. Ann Intern Med 2008; 149: 686–76. <https://doi.org/10.7326/0003-4819-149-9-200811040-00014>
36. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104(12): 3069–79. <https://doi.org/10.1038/ajg.2009.555>
37. Kaboli AR. Comparison of Sequential Regimen and Standard Therapy for Helicobacter pylori Eradication in Patients with Dyspepsia. Scientific J Hamadan Univ Med Sci 2013; 20(3): 193–200.
38. Aminian K. Comparison of three-drug, four-drug and two different Sequential regimens in the treatment of first-line Helicobacter pylori infection. Iranian J Infectious Dis 2009; 1–9.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Archive